Results 251 to 260 of about 4,782 (272)

Therapeutic Response to Single-Inhaler Triple Therapies in Moderate-to-Severe COPD

Respiratory Care, 2023
BACKGROUND: COPD is characterized by progressive and irreversible air flow limitations. Single-inhaler therapies (SITTs) incorporating an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting β 2 -agonist have been shown ...
Kengo, Ohtsuka, Naoko, Harada, Atsuo, Horiuchi, Shintaro, Umemoto, Ryo, Kurabatashi, Akie, Yui, Hiroyuki, Yamamura, Yoko, Shinka, Naoki, Miyao   +8 more
openaire   +2 more sources

Single inhaler triple therapy for COPD

Drug and Therapeutics Bulletin, 2017
The European Medicines Agency (EMA) has granted marketing authorisation for a pressurised metered dose inhaler (pMDI) containing beclometasone dipropionate, formoterol fumarate dihydrate and glycopyrronium bromide (Trimbow – Chiesi Pharmaceuticals) for the treatment of chronic obstructive pulmonary disease (COPD) in patients not adequately treated with
openaire   +2 more sources

Cost-effectiveness of a single inhaler triple therapy versus ICS/LABA in COPD

Ethics and Economics, 2018
Background: IMPACT (InforMing the PAthway of COPD Treatment, NCT02164513), showed superior exacerbation reduction and lung function improvement with single inhaler, once-daily fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) 100/62.5/22μg vs once-daily FF/VI 100/22μg, for patients with moderate/severe COPD.
Alan A Martin, Dhvani Shah, Emma C Goodall, Melanie Schroeder, Nancy Risebrough, Kerigo Ndirangu, Afisi S Ismaila   +6 more
openaire   +1 more source

Triple therapy in a single inhaler: a new option for uncontrolled asthma

The Lancet, 2019
J Mark, FitzGerald, Mohsen, Sadatsafavi
openaire   +2 more sources

Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study

Respiratory Medicine, 2022
David M Mannino, Michael Bogart, Benjamin Wu   +2 more
exaly  

Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain

Chest, 2022
Bernardino Alcazar Navarrete, Antoni Sicras-Mainar   +1 more
exaly  

Single-inhaler triple therapy for prevention of COPD exacerbations

Drug and Therapeutics Bulletin, 2017
openaire   +2 more sources

Open-inhaler versus single-inhaler triple therapy (long-acting muscarinic antagonist, inhaled corticosteroid, and long-acting β2-agonist) in asthma patients: a narrative review

Journal of Asthma, 2023
Michael E Wechsler, John J Oppenheimer
exaly  

Characteristics of patients with asthma using single inhaler triple therapy (SITT) in the USA

Airway pharmacology and treatment, 2023
Stephen G Noorduyn, Kristin Kahle-Wrobleski, Rosirene Paczkowski, Lydia Lee, Phani Veeranki, Mary Johnson, Afisi S Ismaila, Emmeline Igboekwe, Julie Nack, Noelle N Gronroos   +9 more
openaire   +1 more source

“Extrafine single inhaler triple therapy effect on health status, lung function and adherence in COPD patients: A Panhellenic prospective non-interventional study – The TRIBUNE study”

Respiratory Medicine, 2023
Konstantinos Porpodis, Konstantinos Bartziokas, Petros Bakakos   +2 more
exaly